Talphera, Inc. (NASDAQ:TLPH) Sees Large Drop in Short Interest

by · The Cerbat Gem

Talphera, Inc. (NASDAQ:TLPH – Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 69,300 shares, a decline of 33.4% from the March 15th total of 104,100 shares. Based on an average daily trading volume, of 64,700 shares, the short-interest ratio is currently 1.1 days. Currently, 0.4% of the company’s stock are short sold.

Talphera Trading Up 4.3 %

NASDAQ:TLPH traded up $0.02 during trading hours on Friday, hitting $0.48. The stock had a trading volume of 8,233 shares, compared to its average volume of 75,959. Talphera has a 1-year low of $0.45 and a 1-year high of $1.27. The company has a market cap of $8.22 million, a PE ratio of -0.70 and a beta of 0.19. The business has a 50 day simple moving average of $0.56 and a two-hundred day simple moving average of $0.67.

Talphera (NASDAQ:TLPH – Get Free Report) last issued its earnings results on Monday, March 31st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.14. Research analysts expect that Talphera will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TLPH shares. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Tuesday, April 1st.

Read Our Latest Analysis on Talphera

About Talphera

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

Further Reading